Tue, Mar 19, 2024
A A A
Welcome Guest
Free Trial RSS pod
Get FREE trial access to our award winning publications
Alternative Market Briefing

The Corona Fighters Report 55: Asset managers who delivered in the downturn

Monday, July 13, 2020

amb
Bailey McCann, Opalesque New York:

This is our regular report on hedge funds and alternative asset managers who are successfully protecting assets and outperforming the markets during the first months of 2020.

Biomedical companies continue to outperform

Vista Point Capital's flagship biotech fund - Parallax Biomedical Fund was up 2% (est.) in June and is up 11.7% year to date through June 30th. The fund was also up in Q1 2020 and ended 2019 up 54.20% following strong activity in the sector.

Biomedical companies have outperformed in recent months as the demand for covid-related solutions heats up alongside a growing demand for biomedical services overall. Biomedical companies like Moderna, for example, are working on a potential vaccine for Covid-19. The US government's Operation Warp Speed, which provides funding to fastrack the development of a coronavirus vaccine, provided a significant capital injection to a group of biomedical companies that could begin work on a coronavirus vaccine immediately. Most of that funding went to large-cap biomedical companies, but small-cap biomedical companies with products in the pipeline often become targets for acquisition by large-cap companies in this sector.

Parallax makes investments in small-cap biotechnology and medical technology companies. The investment team is typically looking for companies that have later stage products in development or those that have low valuations with room to grow. The strategy takes advantage of the high barriers to entry for biomedical companies. The field is complex and inefficient which lead to dislocations in the stocks that can be beneficial for opportunistic traders. The fund runs a concentrated portfolio of 20-25 core positions and invests in both US and European companies.

Vista Point is led by Marc Pentopolous. Pentopolous founded Katana Pharmaceuticals and has decades of experience in medical technology, drug development, and finance. He also led Emerging Growth Management's medical technology strategy.

Marc Pentopolous will be a presenter in our fourth Corona Fighters webinar discussing the biomedical sector and other portfolio diversifiers. Registration is free.

View prior reports: Report 54

Webinar: The Corona Fighters Episode 4

Meet five more asset managers who delivered during the meltdown.

Time: Tuesday, July 21st, 10 am EST
Details and registration: www.opalesque.com/webinar/


New eBook: The Corona Fighters COLLECTION - A Handbook for Investors

200+ funds that were up or protected assets in Q1 2020: A Compendium of Opalesque Corona Fighters Report #1 to Report #52

Download here: www.opalesque.com/ebook.

***

Disclaimer: This is not investment advice. Opalesque has not verified this information and gives no warranty of accuracy or completeness. Past performance is not indicative of future results. See our Terms & Conditions for more information.

***


WEBINARS:

Meet 15 fund managers and learn how and why their strategies delivered positive returns and/or protected capital during the Corona led market meltdown! Each webinar lasts an hour and features five managers.

"The whole Corona Fighters program has been extremely educational for me and a great opportunity to learn more about hedge funds and compare/contrast their approaches." (Single Family Office Principal)

Video replays of Opalesque's past webinars can be found here: www.opalesque.com/webinar/#pastwebinar

Previous Opalesque Exclusives                                  
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. KKR raises $6.4bn for the largest pan-Asia infrastructure fund[more]

    Laxman Pai, Opalesque Asia: The New York-based global investment firm KKR has raised a record $6.4bn for its second Asia-focused infrastructure fund, underlining investors' continued appetite for private markets. According to a media release from the alternative assets manager, the figure top

  2. Bucking the trend, top hedge fund makes plans for a second SPAC[more]

    From Institutional Investor: SPACs aren't dead. At least not to the folks at Cormorant Asset Management. The life sciences firm, whose hedge fund topped its peers in 2023, is confident it will match the success of its first blank-check company. Last week, the life sciences and biopharma speciali

  3. Benefit Street Partners closes fifth fund on $4.7 billion[more]

    Bailey McCann, Opalesque New York: Benefit Street Partners has closed its fifth flagship direct lending vehicle, BSP Debt Fund V, with $4.7 billion of investable capital across the strategy. Benefit Street invests primarily in privately originated, floating rate, senior secured loans. The fun

  4. 4 hedge fund themes that are working in 2024[more]

    From The Street: A poor earnings report from Tesla (TSLA) has not hurt the indexes on Thursday. The decline in Tesla stock, which is losing its position in the Magnificent Seven pantheon, is more than offset by strong earnings from IBM (IBM) and ServiceNow (NOW) . In addition, the much higher-t

  5. Opalesque Exclusive: A global macro fund eyes opportunities in bonds[more]

    Bailey McCann, Opalesque New York for New Managers: Munich-based ThirdYear Capital rebounded in 2023, following a tough year for global macro. The firm's flagship ART Global Macro strategy finished the year up 1